GRAIL Inc
Research GRAIL Inc (GRAL) on Bullrun: market cap USD 3.69B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGRAL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Market capUSD 3.69B
- Financial periodQ2 2026
- RevenueUSD 44.69M
- Net income-USD 110.25M
- Free cash flow-USD 81.16M
- Gross margin-28.1%
Valuation Snapshot
latest market cap is USD 3.69B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 147.17M | -USD 408.35M | -USD 299.92M | -42.5% | -11.11 | USD 249.73M | USD 54.86M | USD 2.58B |
| FY2024 | USD 125.60M | -USD 2.03B | -USD 582.36M | -62.1% | -63.54 | USD 214.23M | USD 68.14M | USD 2.50B |
| FY2023 | USD 93.11M | -USD 1.47B | -USD 608.69M | n/a | -47.21 | USD 97.29M | USD 84.41M | USD 0 |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.69B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.45B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 605.00M | n/a | n/a | n/a |
About GRAIL Inc
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is GRAIL Inc's market cap?
GRAIL Inc's market capitalization is USD 3.69B.
What does GRAIL Inc do?
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development.